The Portuguese version of the ASQoL performed well, demonstrating good psychometric properties for use in clinical studies and trials of patients with AS. The lack of significance in the analysis by self-perceived disease severity may be due to the relatively small sample size. 
shows that multiple oligonucleotides successfully distinguished SLE patients from all other groups. All significant features were IgG antibodies, except for 1 IgM. Table 2 shows the impact of single nucleotide change on autoantibody binding. PolyG (G17) separates SLE from all but SS. T1G16 separates SLE from HC subjects, while G16T1 gave no significant separation. The addition of a G to the 5' and 3' end of T16 enhanced IgG antibody binding and improved separation between SLE and other autoimmune diseases with at least 10-fold improved significance as compared to T20. PolyG sequence length impacts the ability of the oligonucleotides to separate between SLE and the other groups (Fig.  1A) . Unexpectedly, sequences either shorter or longer than G14 were effective in separating SLE from HC, RA, and SSc, while G14 was not effective. Furthermore, none of the polyG homopolymers could separate SLE from SS. Sequences rich in C or T were more effective at separating between SLE and SS patients (Fig. 1B) . 
Conclusions:
• Autoantibody binding to oligonucleotides can be used to differentiate SLE from other autoimmune conditions and healthy subjects.
• The structural basis for the differences in binding of antibodies from disease sera to the various oligonucleotides is not yet understood, but may be due to immunologically unique conformations and secondary structures of oligonucleotides of defined length and sequence.
• SSc can be differentiated from SLE based on particular antibody binding to epitopes of oligonucleotides containing C and T.
• RA can be differentiated from SLE more significantly than the other autoimmune conditions.
